|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Amebiasis, extraintestinal |
|
Malaria |
| |
|
|
SIDE EFFECTS:
|
|
Ocular toxicity such as corneal opacities, retinopathy, and/or keratopathy |
|
Blood dyscrasias such as agranulocytosis, aplastic anemia, neutropenia, and/or thrombocytopenia |
|
cardiovascular toxicity such as hypotension |
|
prolonged QRS interval |
|
emotional changes or psychosis |
|
neuromyopathy |
|
ototoxicity |
|
seizures |
|
Ciliary muscle dysfunction |
|
gastrointestinal irritation |
|
headache |
|
itching |
|
Bleaching of hair or increased hair loss |
|
blue-black discoloration of skin, fingernails, or inside of mouth |
|
skin rash or itching |
|
Blurred vision or any other change in vision |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Blood disorders, severe |
|
Gastrointestinal disorders, severe |
|
Glucose-6-phosphate dehydrogenase deficiency |
|
>> Hepatic function impairment |
|
Hypersensitivity to chloroquine or hydroxychloroquine |
|
>> Neurological disorders, severe |
|
Porphyria |
|
Psoriasis |
|
>> Retinal or visual field changes, presence of |
|
|
ADULT DOSE:
|
|
Malaria (suppressive treatment)-Oral, 500 mg (300 mg base) once every seven days .
Malaria (treatment)-Oral, 1 gram (600 mg base) initially, followed by 500 mg (300 mg base) in six to eight hours, and 500 mg (300 mg base) once a day on the second and third days .
Liver abscess, amebic (treatment)-In combination with other "tissue-acting" antiprotozoals: Oral, 250 mg (150 mg base) four times a day for two days, followed by 250 mg (150 mg base) two times a day for at least two to three weeks .
Note: The dosage schedule may be revised up or down, if necessary, or the course of therapy may be repeated .
[Antirheumatic (disease-modifying)] -Oral, up to 4 mg (2.4 mg base) per kg of lean body weight daily .
[Lupus erythematosus (suppression)] -Oral, up to 4 mg (2.4 mg base) per kg of lean body weight daily .
[Polymorphous light eruption (suppression)] -Oral, 250 mg (150 mg base) two times a day for two weeks; then 250 mg (150 mg base) once a day . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Malaria (suppressive treatment)-Oral, 8.3 mg (5 mg base) per kg of body weight, not to exceed the adult dose, once every seven days .
Malaria (treatment)-Oral, 41.7 mg (25 mg base) per kg of body weight administered over a period of three days as follows: 16.7 mg (10 mg base) per kg of body weight, not to exceed a single dose of 1 gram (600 mg base); then 8.3 mg (5 mg base) per kg of body weight, not to exceed a single dose of 500 mg (300 mg base), six, twenty-four, and forty-eight hours after the first dose .
Liver abscess, amebic (treatment)-Oral, 10 mg (6 mg base) per kg of body weight (up to a maximum of 500 mg [300 mg base]) per day for three weeks .
Note: Children are especially sensitive to the effects of chloroquine . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|